Patents by Inventor Nicholas Pomato
Nicholas Pomato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8343508Abstract: This invention provides botulinum antitoxin compositions and methods of production, and methods of treating animals and humans prophylactically and also those suspected of having contacted botulism toxin. The botulinum antitoxin is prepared by inoculating an animal with a monovalent botulinum toxoid and toxin. The animal's plasma is collected and purified at a high pH by affinity chromatography. The resulting monovalent immunoglobulins are de-speciated by digestion with pepsin. Monovalent antitoxins for all seven botulinum serotypes are then combined to produce a high titered heptavalent botulinum antitoxin composition.Type: GrantFiled: December 11, 2009Date of Patent: January 1, 2013Assignee: Intracel Holdings LLCInventors: Nicholas Pomato, Martin V. Haspel, Janet H. Ransom
-
Publication number: 20100150934Abstract: This invention provides botulinum antitoxin compositions and methods of production, and methods of treating animals and humans prophylactically and also those suspected of having contacted botulism toxin. The botulinum antitoxin is prepared by inoculating an animal with a monovalent botulinum toxoid and toxin. The animal's plasma is collected and purified at a high pH by affinity chromatography. The resulting monovalent immunoglobulins are de-speciated by digestion with pepsin. Monovalent antitoxins for all seven botulinum serotypes are then combined to produce a high titered heptavalent botulinum antitoxin composition.Type: ApplicationFiled: December 11, 2009Publication date: June 17, 2010Inventors: Nicholas Pomato, Martin V. Haspel, Janet H. Ransom
-
Patent number: 7628996Abstract: This invention relates to methods of removing bioburden from an aggregate of cells to obtain sterile cells that remain viable and immunogenic for the production of vaccines. This invention further relates to a method of eliciting an immune response to prevent a recurrence of metastases that involves preparing and administering a sterile vaccine derived from solid tumors. The vaccine is prepared by excising a solid tumor from a cancer patient, digesting the tumor cells with an enzyme to obtain dissociated cells, irradiating the dissociated cells to render the cells non-tumorigenic, and sterilizing the cells.Type: GrantFiled: February 21, 2003Date of Patent: December 8, 2009Assignee: Intracel Resources LLCInventors: Martin V. Haspel, Nicholas Pomato, Michael G. Hanna, Jr.
-
Publication number: 20050042775Abstract: This invention provides botulinum antitoxin compositions and methods of production, and methods of treating animals and humans prophylactically and also those suspected of having contacted botulism toxin. The botulinum antitoxin is prepared by inoculating an animal with a monovalent botulinum toxoid and toxin. The animal's plasma is collected and purified at a high pH by affinity chromatography. The resulting monovalent immunoglobulins are de-speciated by digestion with pepsin. Monovalent antitoxins for all seven botulinum serotypes are then combined to produce a high titered heptavalent botulinum antitoxin composition.Type: ApplicationFiled: May 19, 2004Publication date: February 24, 2005Inventors: Nicholas Pomato, Martin Haspel, Janet Ransom
-
Publication number: 20030228300Abstract: This invention relates to methods of removing bioburden from an aggregate of cells to obtain sterile cells that remain viable and immunogenic for the production of vaccines. This invention further relates to a method of eliciting an immune response to prevent a recurrence of metastases that involves preparing and administering a sterile vaccine derived from solid tumors. The vaccine is prepared by excising a solid tumor from a cancer patient, digesting the tumor cells with an enzyme to obtain dissociated cells, irradiating the dissociated cells to render the cells non-tumorigenic, and sterilizing the cells.Type: ApplicationFiled: February 21, 2003Publication date: December 11, 2003Inventors: Martin V. Haspel, Nicholas Pomato, Michael G. Hanna
-
Patent number: 5965106Abstract: A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog. Preferably, the affinity component is thermo-stabilized.Type: GrantFiled: June 5, 1995Date of Patent: October 12, 1999Assignee: PerImmune Holdings, Inc.Inventors: Nicholas Pomato, Richard P. McCabe, Gregory A. Hawkins, Reinhard Bredehorst, Chong-Ho Kim, Carl-Wilhelm Vogel
-
Patent number: 5951985Abstract: This invention relates to the epitopes to which monoclonal antibody 88BV59 and antibody 16.88 react. These antibodies were produced by B-cell lines derived from B-cells of cancer patients actively immunized with autologous tumor antigens. Both epitopes are found on the same antigen in tumor tissue. These epitopes can be used in both diagnostic procedures and therapy for human cancers.Type: GrantFiled: August 19, 1997Date of Patent: September 14, 1999Assignee: Perimmune Holdings, Inc.Inventors: Sandra M. Butler, Nicholas Pomato, Ebo Bos, Michael G. Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr.
-
Patent number: 5807534Abstract: A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog.Type: GrantFiled: May 30, 1995Date of Patent: September 15, 1998Assignee: Akzo Nobel N.V.Inventors: Nicholas Pomato, Richard P. McCabe, Gregory Alan Hawkins, Reinhard Bredehorst, Chong-Ho Kim, Carl-Wilhelm Ernst Vogel
-
Patent number: 5705634Abstract: The present invention is directed to a new process for the production of chitin oligomers, including fragmentation, partial hydrolysis and recovery. This process produces high yields, especially of higher (tetra- to deca-) chitin oligomers.Type: GrantFiled: March 2, 1995Date of Patent: January 6, 1998Assignee: PerImmune Holdings, Inc.Inventors: Reinhard Bredehorst, Nicholas Pomato, Oliver Scheel, Joachim Thiem
-
Patent number: 5595738Abstract: A lipid antigen found in colon, breast, lung, ovarian and pancreatic human adenocarcinomas identified by reactivity with human monoclonal antibody 81AV78, and the use of the antigen in vaccines.Type: GrantFiled: December 6, 1993Date of Patent: January 21, 1997Assignee: Akzo Nobel N.V.Inventors: Nicholas Pomato, Janet H. Ransom
-
Patent number: 5578289Abstract: A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog.Type: GrantFiled: November 4, 1993Date of Patent: November 26, 1996Assignee: Akzo N.V.Inventors: Nicholas Pomato, Richard P. McCabe, Gregory A. Hawkins, Reinhard Bredehorst, Chong-Ho Kim, Carl-Wilhelm E. Vogel
-
Patent number: 5521285Abstract: The present invention comprises the epitope recognized by the human monoclonal antibody 28A32, the human tumor antigen containing this epitope, which we have identified, isolated and characterized, and human MCA 28A32. The invention also relates to the use of antibodies to the antigen containing this epitope for diagnosis and monitoring of treatment of cancer and to the use of this antigen in the preparation of vaccines to elicit an immune response similar to that obtained against tumor cells containing this epitope.Type: GrantFiled: April 1, 1993Date of Patent: May 28, 1996Assignee: Akzo Nobel N.V.Inventors: Nicholas Pomato, Ebo S. Bos, Janet H. Ransom, Michael G. Hanna, Jr.
-
Patent number: 5433955Abstract: A method for site-specific in-vivo activation of a prodrug in an animal using an activator-targeting moiety conjugate to localize an activator at a predetermined site of use and a prodrug compound that is converted to an active drug in the presence of the activator. In the preferred embodiment, the targeting moiety, the activator, and the prodrug demonstrate little or no immunogenicity in the animal being treated. The targeting moiety is relatively specific for binding to the target tissue than to non-target tissue. The activator is not found or present in only small amounts in circulation or in non-target tissue, does not have a substrate for its activity in circulation or in non-target tissue, can be linked to the targeting moiety, and is capable of converting the prodrug to an active drug. The prodrug is selected for its ability to exert a cytotoxic activity on the target tissue after conversion by the activator.Type: GrantFiled: October 8, 1993Date of Patent: July 18, 1995Assignee: Akzo N.V.Inventors: Reinhard Bredehorst, Chong-Ho Kim, Richard McCabe, Nicholas Pomato, Carl-Wilhelm Vogel
-
Patent number: 5338832Abstract: The present invention comprises the epitope recognized by the human monoclonal antibody 16-18, the human tumor antigen containing this epitope, which we have identified, isolated and characterized, and anti-idiotypic antibodies to human MCA 16-88, which comprise the same epitope. The invention also relates to the use of antibodies to the antigen containing this epitope for diagnosis and monitoring of treatment of cancer and to the use of this antigen in the preparation of vaccines to elicit an immune response similar to that obtained against tumor cells containing this epitope.Type: GrantFiled: August 13, 1992Date of Patent: August 16, 1994Assignee: Akzo N.V.Inventors: Nicholas Pomato, Ebo S. Bos, Martin V. Haspel, Michael G. Hanna, Jr., Michael L. Berman
-
Patent number: 4849506Abstract: Leukoregulin is identified, a biologically active lymphokine of molecular weight of about 120,000 to 140,000, with subunits of about 30,000 to 35,000, having the isoelectric focusing pH's of between 4.8 and 5.5 or between 7.5 and 8.3, which has the ability to regulate tumor cell physiology and growth without affecting the growth of normal cells. Methods for stimulating its production by monouclear cells, methods for its isolation and purification, and methods for its therapeutic uses are also disclosed.Type: GrantFiled: September 11, 1986Date of Patent: July 18, 1989Assignee: Akzo N.V.Inventors: Janet H. Ransom, Richard P. McCabe, Martin V. Haspel, Nicholas Pomato